Orthofix cuts 2026 guidance, withdraws three-year targets on Medicare reimbursement cuts

Filed May 21, 2026 · Period ending May 21, 2026 · ~1 min read

Key Changes

• high

  Medicare reimbursement for bone growth stimulators drops ~10% effective May 18, 2026, following FDA device reclassification from Class III to Class II.

  Item 7.01 verify on EDGAR →
• high

  Full-year 2026 revenue guidance lowered to $838-$848 million, adjusted EBITDA to $90-$93 million; company now expects negative free cash flow for the year.

  Item 7.01 verify on EDGAR →
• high

  Three-year financial targets withdrawn due to uncertainty around long-term impact of current and potential future CMS reimbursement changes.

  Item 7.01 verify on EDGAR →